LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
To monitor treatment for ovarian cancer or to detect recurrence; sometimes to evaluate a lump located in the pelvic area (pelvic mass); not recommended for screening asymptomatic women but sometimes ordered to help detect early ovarian cancer in those identified as being at high risk
Before starting therapy for ovarian cancer and at intervals during and after treatment; sometimes when you have a pelvic mass or are at a high risk for developing ovarian cancer
A blood sample drawn from a vein in your arm
Cancer Antigen 125 (CA-125) is a protein that is present on the surface of most, but not all, ovarian cancer cells. This makes the test useful as a tumor marker in specific circumstances. The CA-125 test measures the amount of CA-125 in the blood.
Significantly elevated concentrations of CA-125 may be present in the blood of a woman who has ovarian cancer. Thus the test may be used to monitor the effectiveness of treatment and/or for recurrence of the cancer. However, not all women with ovarian cancer will have elevated CA-125 so the test may not be useful in all cases.
Ovarian cancer is the fifth most common cause of cancer death in women. According to the American Cancer Society (ACS), the lifetime risk of a woman developing ovarian cancer is about 1 in 75 and the lifetime risk of death is 1 in 100. ACS estimates that about 22,000 new cases are diagnosed each year in the U.S. and about 14,000 women die of it.
Currently, less than 20% of ovarian cancers are found in the early stages before they have spread outside the ovary. The primary reason they go undetected is that the symptoms of ovarian cancer are fairly non-specific.
The need for a reliable method for early detection of ovarian cancer among asymptomatic women continues to drive ongoing research. In the meantime, regular physicals, pelvic exams, and an awareness of family history and symptoms are important.
CA-125 is not recommended as a screening test for asymptomatic women because it is non-specific. Small quantities of CA-125 are produced by normal tissues throughout the body and by some other cancers. Levels in the blood may be moderately elevated with a variety of non-cancerous conditions, including menstruation, pregnancy, and pelvic inflammatory disease.
Cancer Antigen 125 (CA-125) is a tumor marker primarily used to monitor therapy during treatment for ovarian cancer. CA-125 is also used to detect whether cancer has come back after treatment is complete. A series of CA-125 tests that shows rising or falling concentrations is often more useful than a single result.
CA-125 is sometimes used along with transvaginal ultrasound to test and monitor women who have a high risk for ovarian cancer but who do not yet have the disease. The most significant risk factor for ovarian cancer is an inherited genetic mutation in one of two genes: breast cancer gene1 (BRCA1) or breast cancer gene 2 (BRCA2). Other risk factors are family history, increasing age, reproductive history and infertility, use of hormone replacement therapy, and obesity.
Sometimes a CA-125 test may be ordered along with a transvaginal ultrasound to help investigate a lump in woman's lower abdominal area (pelvic mass.)
The test is not used, however, to screen women for ovarian cancer because it is non-specific. The U.S. Preventive Services Task Force recommends against screening women for ovarian cancer. This recommendation applies to asymptomatic women but not to women at high risk for developing ovarian cancer, such as those with a genetic mutation.
Currently, there is no one reliable method for early detection of ovarian cancer among asymptomatic women. Less than 20% of ovarian cancers are found in the early stages before they have spread outside the ovary. One reason they go undetected is that the symptoms of ovarian cancer are fairly non-specific. In the meantime, regular physicals, pelvic exams, and an awareness of family history and other risk factors are important. (For more about ovarian cancer, see the "What is being tested?" section or the article on Ovarian Cancer.)
The CA-125 test may be ordered before a woman starts ovarian cancer treatment as a baseline to compare against future measurements. During therapy, a healthcare practitioner may order CA-125 testing at intervals to monitor response to therapy. CA-125 may also be measured periodically after therapy is completed.
In some cases, a healthcare practitioner may order a CA-125 test when a woman has a pelvic mass in order to help determine the cause.
Some healthcare providers may order a CA-125 test and a transvaginal ultrasound at regular intervals when a woman is at high risk of developing ovarian cancer.
If CA-125 levels fall during therapy, this generally indicates that the cancer is responding to treatment. If CA-125 levels rise or stay the same, then the cancer may not be responding to therapy. High CA-125 levels after treatment is complete may indicate that the cancer has come back.
If a woman who has been diagnosed with ovarian cancer has a baseline CA-125 level that is normal, then the test is not likely to be useful to monitor her ovarian cancer. In this case, the ovarian cancer may not be producing CA-125 and is not a good marker of disease progression.
In a woman with a pelvic mass, and in a woman with a high risk for developing ovarian cancer, a significantly elevated CA-125 is a concern but does not necessarily indicate ovarian cancer. This finding would prompt further testing and evaluation.
Because CA-125 can be high in many normal or benign conditions, such as pregnancy, menstruation, endometriosis, and pelvic inflammatory disease, it is not useful or recommended as a screening test for the general population.
A new tumor marker, human epididymis protein 4 (HE4), may be ordered along with CA-125 to monitor epithelial cell tumors, the most common type of ovarian cancers. These cancers develop from the cells that cover the outside of the ovaries. The use and full clinical utility of this test has yet to be determined.
No, not all ovarian cancers are associated with increased levels of CA-125. Elevated levels have been found in about 80% of women with ovarian cancer.
Family history is a risk factor for ovarian cancer. If you have close family members who have had ovarian cancer, you are at higher risk than someone who has no family history of the disease. Make sure your healthcare providers know about your family medical history. Women who have inherited a mutation in one of the BRCA genes are at high risk of ovarian cancer. For more details, see the article on BRCA1 and BRCA2.
In addition to family history, other risk factors include increasing age, obesity, and use of hormone replacement therapy. See the American Cancer Society web site for more on this.
Sources Used in Current Review
2016 review by Carolyn Sue Ziegler, MBA, MLS(CM).
Pagana, Kathleen D, Pagana, Timothy J, and Pagana, Theresa N. (©2015) Mosby’s Diagnostic & Laboratory Test Reference 12th Edition: Mosby, Inc. Saint Louis, MO. Pp.199-200.
(Updated Oct. 30, 2015) Gentry George T King, M.D. CA 125: Reference Range, Interpretation, Collection and Panels. Available online at http://emedicine.medscape.com/article/2087557-overview. Accessed 23/2016.
Ovarian Cancer National Alliance. Risk Factors. Available online at http://www.ovariancancer.org/about/risk-factors. Accessed 2/8/2016.
Ovarian Cancer National Alliance. Symptoms and Detection of Ovarian Cancer. Available online at http://www.ovariancancer.org/about/symptoms-of-ovarian-cancer-detection. Accessed 2/8/2016.
(Updated 13 January 2016) CA-125 blood test. MedlinePlus Medical Encyclopedia. Available online at https://www.nlm.nih.gov/medlineplus/ency/article/007217.htm. Accessed 2/3/2016.
(©2016) Mayo Clinic Mayo Medical Laboratories. Human Epididymis Protein 4, Serum. Available online at http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/62137. Accessed 2/10/2016.
Ovarian Cancer Testing: HE4 Ovarian Cancer Monitoring. Quest Diagnostics. Available online at http://www.questdiagnostics.com/home/patients/tests-a-z/ovarian-cancer/he4-monitoring.html. Accessed Feb 2016.
(©2014) Laboratory Corporation of America. A Technical Review, Human Epididymis Protein 4 (HE4), Monitoring Patients With Epithelial Ovarian Carcinoma.
(Jan 14, 2015) Fazal Hussain. Gynecologic Tumor Markers, Cancer Antigen 125. Medscape Review. Available online at http://emedicine.medscape.com/article/269839-overview#a2. Accessed 2/8/2016.
(Aug 5, 2014) American Cancer Society. Ovarian Cancer: Detailed Guide. Available online at http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-what-is-ovarian-cancer. Accessed 2/8/2016.
Sources Used in Previous Reviews
Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].
Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.
Pagana, K. D. & Pagana, T. J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 219-220.
Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 210-211.
Mason, J. (Updated 2008 June 10). CA-125. MedlinePlus Medical Encyclopedia. [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/007217.htm. Accessed March 2009.
(2007 March). Ovarian Cancer Resource Guide for women with recurrent disease. NOCC, Inc. [On-line information]. PDF available for download at http://www.ovarian.org/Images/ResourceGuideRecurrentOvarianCancer.pdf. Accessed March 2009.
(2008 August 26). Ovarian Cancer: Why Screening Isn't Routine. American Cancer Society. [On-line information]. Available online at http://www.cancer.org/docroot/SPC/content/SPC_1_ovarian_Q_A_Saslow.asp. Accessed March 2009.
(Modified 2008 April 3). Ovarian Cancer Screening (PDQ®), Health Professional Version. NCI, U.S. National Institutes of Health. [On-line information]. Available online at http://www.cancer.gov/cancertopics/pdq/screening/ovarian/healthprofessional. Accessed March 2009.
(2008 July). Understanding CA 125 Levels: A Guide for Ovarian Cancer Patients. Gynecologic Cancer Foundation. [On-line information]. PDF available for download at http://www.thegcf.org/wcnlib/downloads/CA125levels_July2008.pdf. Accessed March 2009.
(Updated 2012 August 1). Fazal Hussain, F. and Homoud, H. Gynecologic Tumor Markers Tumor Marker Overview. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/269839-overview. Accessed October 2012.
Zieve, D. and Chen Y. (Updated 2011 December 15). CA-125. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/007217.htm. Accessed October 2012.
(Revised 2012 October 5). Can ovarian cancer be found early? American Cancer Society [On-line information]. Available online at http://www.cancer.org/cancer/ovariancancer/detailedguide/ovarian-cancer-detection. Accessed October 2012.
Grenache, D. et. al. (Updated 2012 May). Ovarian Cancer. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/OvarianCancer.html?client_ID=LTD. Accessed October 2012.
Schmidt, C. (2011 December 05). CA-125: A Biomarker Put to the Test. Medscape Today News from J Natl Cancer Inst. V 103(17):1290-1281 [On-line information]. Available online at http://www.medscape.com/viewarticle/750770. Accessed October 2012.
Rustin, G. et. al. (2012 March 08). CA-125: To Monitor or Not to Monitor? For Ovarian Cancer Patients in Remission. Medscape Today News [On-line information]. Available online at http://www.medscape.com/viewarticle/759809. Accessed October 2012.
(2012 September). Screening for Ovarian Cancer, U.S. Preventive Services Task Force Reaffirmation Recommendation Statement. USPSTF [On-line information]. Available online at http://www.uspreventiveservicestaskforce.org/uspstf12/ovarian/ovarcancerrs.htm. Accessed November 2012.
Pagana, K. D. & Pagana, T. J. (© 2011). Mosby's Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 210-211.
Clarke, W., Editor (© 2011). Contemporary Practice in Clinical Chemistry 2nd Edition: AACC Press, Washington, DC. Pp 499-500.